Discover
ADAG
Adagene Inc.
2.76
2 x 2.56
3 x 4.00
bid
ask
-
0.02
0.72%
3 @ 04:00 PM
2.76 +0.00 (0.00%)
| Ytd | 46.03% | |
| 1y | 41.54% |
2.63
day range
2.87
1.40
52 week range
4.78
| Open | 2.76 | Prev Close | 2.78 | Low | 2.63 | High | 2.87 | Mkt Cap | 185.32M |
| Vol | 1.65M | Avg Vol | 244.76K | EPS | -0.37 | P/E | N/A | Forward P/E | -2.81 |
| Beta | 0.58 | Short Ratio | 0.66 | Inst. Own | 25.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 3.51 | 200-d Avg | 3.37 | 1yr Est | 8.03 |
ADAG News
benzinga.com
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in t
benzinga.com
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology com
benzinga.com
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rati